← Back to Search

Monoclonal Antibodies

Mirvetuximab for Ovarian Cancer

Saint Petersburg, FL
Phase 2
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have at least 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the Investigator)
Patients must be ≥ 18 years of age
Must not have
Patients with a history of other malignancy within 3 years prior to enrollment
Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests Mirvetuximab Soravtansine, a treatment that targets and kills specific cancer cells, in patients with certain recurrent ovarian, primary peritoneal, or fallopian tube cancers. It works by using an antibody to deliver a cancer-killing drug directly to the cancer cells. Mirvetuximab Soravtansine has shown promise in treating certain types of ovarian cancer.

See full description
Who is the study for?
This trial is for adults over 18 with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer that's sensitive to platinum-based therapy. They must have had at least two prior platinum treatments (or one if allergic) and show progression after the last treatment. Participants need measurable disease by RECIST v1.1 standards, confirmed FRα positivity, and adequate organ function. Women of childbearing age must use contraception.Check my eligibility
What is being tested?
The PICCOLO study is testing Mirvetuximab Soravtansine as a single-agent treatment in participants with specific types of cancer that express high levels of folate receptor-alpha (FRα). It's an open-label Phase 2 trial focusing on safety and effectiveness in those who've shown sensitivity to platinum-based chemotherapy.See study design
What are the potential side effects?
While not explicitly listed here, potential side effects may include typical reactions to monoclonal antibodies such as infusion-related reactions, fatigue, digestive issues like nausea or diarrhea, skin rash or itching, low blood counts leading to increased infection risk or bleeding tendencies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have at least one tumor that can be measured with a scan.
 show original
Select...
I am 18 years old or older.
 show original
Select...
I am willing to provide a sample of my tumor for testing.
 show original
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
 show original
Select...
I have been tested for BRCA mutation and received PARP inhibitor therapy if positive.
 show original
Select...
I have been diagnosed with high-grade serous ovarian, peritoneal, or fallopian tube cancer.
 show original
Select...
My cancer has worsened after my last cancer treatment.
 show original
Select...
My tumor is positive for a specific protein according to a special test.
 show original
Select...
My cancer returned more than 6 months after my last platinum-based treatment.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had any other cancer in the last 3 years.
 show original
Select...
I have severe liver disease.
 show original
Select...
I have previously been treated with MIRV or drugs targeting FRα.
 show original
Select...
I have brain metastases that are either untreated or causing symptoms.
 show original
Select...
My ovarian cancer is of a specific type, such as endometrioid or clear cell.
 show original
Select...
I have ongoing eye problems like uncontrolled glaucoma or need treatments for my eyes.
 show original
Select...
I have a history of MS, demyelinating disease, or Lambert-Eaton syndrome.
 show original
Select...
I have been diagnosed with a non-infectious lung condition.
 show original
Select...
I am not pregnant or breastfeeding.
 show original
Select...
I do not have severe numbness or pain in my hands or feet.
 show original
Select...
I have had radiotherapy that affected a significant part of my bone marrow.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assess Objective Response Rate
Secondary study objectives
Assess Cancer Antigen-125
Assess Duration of response (DOR)
Assess Overall survival (OS)
+3 more

Side effects data

From 2020 Phase 3 trial • 366 Patients • NCT02631876
54%
Nausea
44%
Diarrhoea
43%
Vision blurred
34%
Fatigue
33%
Abdominal pain
32%
Keratopathy
28%
Dry eye
26%
Constipation
26%
Vomiting
25%
Decreased appetite
23%
Headache
21%
Asthenia
21%
Visual acuity reduced
20%
Neuropathy peripheral
18%
Aspartate aminotransferase increased
16%
Alanine aminotransferase increased
16%
Cough
16%
Hypomagnesaemia
15%
Cataract
15%
Dyspnoea
15%
Arthralgia
14%
Photophobia
14%
Anaemia
13%
Eye pain
12%
Urinary tract infection
12%
Dysgeusia
11%
Thrombocytopenia
11%
Abdominal distension
10%
Pyrexia
10%
Peripheral sensory neuropathy
10%
Muscle spasms
9%
Insomnia
9%
Back pain
9%
Myalgia
8%
Blood alkaline phosphatase increased
7%
Hypertension
7%
Weight decreased
7%
Neutropenia
7%
Dizziness
7%
Hypokalaemia
7%
Dyspepsia
6%
Anxiety
6%
Paraesthesia
6%
Hypoalbuminaemia
6%
Abdominal pain upper
6%
Gastrooesophageal reflux disease
6%
Pain in extremity
5%
Pruritus
5%
Nasopharyngitis
5%
Dry mouth
5%
Pneumonitis
5%
Hyperglycaemia
5%
Vitreous floaters
5%
Muscular weakness
5%
Musculoskeletal pain
4%
Upper respiratory tract infection
4%
Nasal congestion
4%
Neurotoxicity
4%
Dehydration
4%
Intestinal obstruction
4%
Abdominal pain lower
4%
Stomatitis
4%
Ascites
4%
Visual impairment
4%
Leukopenia
4%
Rash
4%
Foreign body sensation in eyes
4%
Hyponatraemia
4%
Non-cardiac chest pain
3%
Flushing
3%
Tachycardia
3%
Oedema peripheral
3%
Erythema
3%
Epistaxis
3%
Cystitis
3%
Haematuria
3%
Gamma-glutamyltransferase increased
3%
Abdominal discomfort
3%
Flatulence
3%
Keratitis
3%
Eye irritation
3%
Infusion related reaction
3%
Lymphopenia
3%
Alopecia
3%
Chills
2%
Lacrimation increased
2%
Fall
2%
Blood creatinine increased
2%
Weight increased
2%
Corneal deposits
2%
Dry skin
2%
Hot flush
2%
Micturition urgency
2%
Urinary incontinence
2%
Hypoaesthesia
2%
Dysphonia
2%
Productive cough
2%
Peripheral swelling
2%
Influenza
2%
Conjunctivitis
2%
Pollakiuria
2%
Dysuria
2%
Depression
2%
Tinnitus
2%
Vaginal haemorrhage
2%
Sciatica
2%
Transaminases increased
2%
Intraocular pressure increased
2%
Pleural effusion
2%
Small intestinal obstruction
2%
Large intestinal obstruction
2%
Influenza like illness
2%
Malaise
2%
Pain
2%
Respiratory tract infection
2%
Pharyngitis
2%
Eye pruritus
2%
Ocular discomfort
2%
Punctate keratitis
2%
Hypophosphataemia
2%
Hyperuricaemia
2%
Hypocalcaemia
2%
Oropharyngeal pain
2%
Flank pain
1%
Rectal haemorrhage
1%
Chalazion
1%
Conjunctival haemorrhage
1%
Oral herpes
1%
Viral upper respiratory tract infection
1%
Peripheral motor neuropathy
1%
Hyperbilirubinaemia
1%
Uveitis
1%
Mobility decreased
1%
Cardiac arrest
1%
Presyncope
1%
Activated partial thromboplastin time prolonged
1%
Musculoskeletal chest pain
1%
Blood bilirubin increased
1%
Photopsia
1%
Tremor
1%
Leukocytosis
1%
Urinary retention
1%
Conjunctival hyperaemia
1%
Glaucoma
1%
Haematoma
1%
Deep vein thrombosis
1%
Retching
1%
Gingival bleeding
1%
Odynophagia
1%
Cyst
1%
General physical health deterioration
1%
Mucosal inflammation
1%
Lacrimation decreased
1%
Metamorphopsia
1%
Xerophthalmia
1%
Neck pain
1%
Arthritis
1%
Musculoskeletal stiffness
1%
Pneumonia
1%
Sinusitis
1%
Cellulitis
1%
Gingivitis
1%
Embolism
1%
Disturbance in attention
1%
Lethargy
1%
Groin pain
1%
Depressed mood
1%
Dyspareunia
1%
Pelvic pain
1%
Laceration
1%
Bone pain
1%
Ligament sprain
1%
Pulmonary embolism
1%
Agitation
1%
Proteinuria
1%
Ear pain
1%
Sepsis
1%
Syncope
1%
Balance disorder
1%
Neuralgia
1%
Dyspnoea exertional
1%
Lung disorder
1%
Palpitations
1%
Hyperhidrosis
1%
Sinus tachycardia
1%
Pleuritic pain
1%
Rhinorrhoea
1%
Hepatic enzyme increased
1%
Urine leukocyte esterase positive
1%
Contusion
1%
Urinary tract obstruction
1%
Vertigo
1%
Ocular hyperaemia
1%
Chest discomfort
1%
Adverse drug reaction
1%
Chest pain
1%
Herpes zoster
1%
Hepatotoxicity
1%
Gastroenteritis
1%
Ear infection
1%
Injection site bruising
1%
Blepharitis
1%
Diplopia
1%
Asthenopia
1%
Hypercalcaemia
1%
Sinus congestion
1%
Photosensitivity reaction
1%
Night sweats
1%
Petechiae
1%
Rash maculo-papular
1%
Vulvovaginal pain
1%
Vulvovaginal pruritus
1%
Aphthous ulcer
100%
80%
60%
40%
20%
0%
Study treatment Arm
Mirvetuximab Soravtansine
Investigator's Choice (IC) Chemotherapy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Mirvetuximab SoravtansineExperimental Treatment1 Intervention
Participants will receive MIRV 6.0 mg/kg adjusted by ideal body weight (AIBW)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mirvetuximab soravtansine
2012
Completed Phase 3
~920

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ovarian cancer include chemotherapy, PARP inhibitors, and antibody-drug conjugates (ADCs). Chemotherapy agents like paclitaxel and carboplatin work by disrupting cell division, leading to cancer cell death. PARP inhibitors, such as olaparib, target cancer cells with BRCA mutations by preventing DNA repair, causing cell death. Mirvetuximab Soravtansine, an ADC, combines an antibody targeting folate receptor-alpha (overexpressed in ovarian cancer cells) with a cytotoxic drug, delivering the drug directly to cancer cells and minimizing damage to healthy cells. These mechanisms are crucial as they offer targeted and effective treatment options, potentially improving outcomes and reducing side effects for ovarian cancer patients.
Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation <i>BRCA1</i>-Del ex9-12.Promising novel therapies for the treatment of endometrial cancer.

Find a Location

Closest Location:Zangmeister Cancer Center / Sarah Cannon Research Institute· Columbus, OH· 4 miles

Who is running the clinical trial?

AbbVieLead Sponsor
1,070 Previous Clinical Trials
532,459 Total Patients Enrolled
ImmunoGen, Inc.Lead Sponsor
32 Previous Clinical Trials
3,942 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
484 Previous Clinical Trials
170,378 Total Patients Enrolled

Media Library

Mirvetuximab Soravtansine (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05041257 — Phase 2
Peritoneal Neoplasm Research Study Groups: Mirvetuximab Soravtansine
Peritoneal Neoplasm Clinical Trial 2023: Mirvetuximab Soravtansine Highlights & Side Effects. Trial Name: NCT05041257 — Phase 2
Mirvetuximab Soravtansine (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05041257 — Phase 2
~18 spots leftby Mar 2026